The clinical research of Mesylate apatinib combined with docetaxel and S-1 as the first-line treatment of metastatic gastric cancer

Trial Profile

The clinical research of Mesylate apatinib combined with docetaxel and S-1 as the first-line treatment of metastatic gastric cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 May 2017

At a glance

  • Drugs Apatinib (Primary) ; Docetaxel (Primary) ; Gimeracil/oteracil/tegafur (Primary)
  • Indications Adenocarcinoma; Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 May 2017 Planned End Date changed from 15 Nov 2019 to 20 Nov 2019.
    • 16 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top